We are live on ! Find out more
IRD

Opus Genetics

59 hedge funds and large institutions have $55.9M invested in Opus Genetics in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,024% more call options, than puts

Call options by funds: $191K | Put options by funds: $17K

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

138% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 8

74% more capital invested

Capital invested by funds: $32.1M → $55.9M (+$23.8M)

23% more funds holding

Funds holding: 4859 (+11)

8.55% more ownership

Funds ownership: 31.78%40.33% (+8.6%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
59
Holders Change
+11
Holders Change %
+22.92%
% of All Funds
0.72%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
16
Increased
19
Reduced
8
Closed
5
Calls
$191K
Puts
$17K
Net Calls
+$174K
Net Calls Change
+$173K

IRD Hedge Fund Activity: Q4 2025 in Review

59 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2025, worth a combined $55.9M — up 74% from $32.1M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new IRD positions and 5 closed out — a net gain of 11 holders — while 19 added to existing stakes and 8 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $5.52M. The largest seller was Voss Capital, cutting an estimated $245K.

  • 59 institutional investors held Opus Genetics (IRD) as of Q4 2025, up from 48 in Q3 2025.
  • Funds reported $55.9M of Opus Genetics stock for Q4 2025, up 74% quarter-over-quarter.
  • 16 funds opened new Opus Genetics positions in Q4 2025 and 5 closed out, a net change of +11 holders.
  • The largest Opus Genetics buyer in Q4 2025 was Balyasny Asset Management, an estimated $5.52M added.
  • The largest Opus Genetics seller in Q4 2025 was Voss Capital, an estimated $245K sold.

Based on aggregated 13F filings for Q4 2025.